{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T15:27:09Z","timestamp":1787412429555,"version":"build-2736575974"},"reference-count":25,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Taibah University Medical Sciences"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jtumed.2026.07.003","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T16:13:21Z","timestamp":1784564001000},"page":"793-801","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect of dapagliflozin on mineral homeostasis in patients with type 2 diabetes: A real-world retrospective cohort study"],"prefix":"10.1016","volume":"21","author":[{"given":"Tahani","family":"Alshammeri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5906-7339","authenticated-orcid":false,"given":"Ibrahim","family":"El Sayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalia","family":"Abdelazim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jtumed.2026.07.003_bib1","doi-asserted-by":"crossref","first-page":"717","DOI":"10.2337\/dc16-0041","article-title":"SGLT2 inhibitors and cardiovascular risk: lessons learned from the EMPA-REG OUTCOME study","volume":"39","author":"Abdul-Ghani","year":"2016","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.jtumed.2026.07.003_bib16","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.2337\/dci22-0034","article-title":"Management of hyperglycemia in type 2 diabetes, 2022: a consensus report by the American Diabetes Association and the European Association for the Study of Diabetes","volume":"45","author":"Davies","year":"2022","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.jtumed.2026.07.003_bib3","first-page":"1","article-title":"The prevalence and risk factors of type 2 diabetes mellitus in a suburban Saudi population","volume":"17","author":"Al Mansour","year":"2020","journal-title":"Int J Environ Res Publ Health"},{"issue":"3","key":"10.1016\/j.jtumed.2026.07.003_bib4","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1007\/s13410-022-01092-1","article-title":"National and regional prevalence rates of diabetes in Saudi Arabia: analysis of national survey data","volume":"43","author":"Alqahtani","year":"2023","journal-title":"Int J Diabetes Dev Ctries"},{"issue":"7","key":"10.1016\/j.jtumed.2026.07.003_bib18","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.2337\/dc16-0330","article-title":"CV protection in the EMPA-REG OUTCOME trial: a \u201cthrifty substrate\u201d hypothesis","volume":"39","author":"Ferrannini","year":"2016","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.jtumed.2026.07.003_bib24","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jtumed.2026.07.003_bib25","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtumed.2026.07.003_bib7","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1741-7015-11-43","article-title":"Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial","volume":"11","author":"Bailey","year":"2013","journal-title":"BMC Med"},{"issue":"12","key":"10.1016\/j.jtumed.2026.07.003_bib9","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.cardfail.2021.07.003","article-title":"The potential roles of osmotic and nonosmotic sodium handling in mediating the effects of SGLT2 inhibitors on heart failure","volume":"27","author":"Bjornstad","year":"2021","journal-title":"J Card Fail"},{"issue":"11","key":"10.1016\/j.jtumed.2026.07.003_bib14","doi-asserted-by":"crossref","first-page":"e10242","DOI":"10.1002\/jbm4.10242","article-title":"Mineral and electrolyte disorders with SGLT2i therapy","volume":"3","author":"Cianciolo","year":"2019","journal-title":"JBMR Plus"},{"issue":"4","key":"10.1016\/j.jtumed.2026.07.003_bib20","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1097\/01.mnh.0000447022.51722.f4","article-title":"Sodium homeostasis and bone","volume":"23","author":"Hannon","year":"2014","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"8","key":"10.1016\/j.jtumed.2026.07.003_bib10","doi-asserted-by":"crossref","first-page":"e99123","DOI":"10.1172\/jci.insight.99123","article-title":"Canagliflozin triggers the FGF23\/1,25-dihydroxyvitamin D\/parathyroid hormone axis in healthy volunteers","volume":"3","author":"Blau","year":"2018","journal-title":"JCI Insight"},{"issue":"8","key":"10.1016\/j.jtumed.2026.07.003_bib11","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1359\/jbmr.060507","article-title":"Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women","volume":"21","author":"Burnett","year":"2006","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jtumed.2026.07.003_bib17","doi-asserted-by":"crossref","first-page":"918350","DOI":"10.3389\/fendo.2022.918350","article-title":"The extraglycemic effect of SGLT-2 inhibitors on mineral and bone metabolism and bone fracture","volume":"13","author":"Dong","year":"2022","journal-title":"Front Endocrinol"},{"issue":"1","key":"10.1016\/j.jtumed.2026.07.003_bib23","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S2213-8587(14)70227-X","article-title":"Possible adverse effects of SGLT2 inhibitors on bone","volume":"3","author":"Taylor","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"10.1016\/j.jtumed.2026.07.003_bib2","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1080\/03007995.2016.1174841","article-title":"The effects of canagliflozin, a sodium\u2013glucose cotransporter 2 inhibitor, on mineral metabolism and bone in patients with type 2 diabetes mellitus","volume":"32","author":"Alba","year":"2016","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"10.1016\/j.jtumed.2026.07.003_bib19","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s13300-017-0232-0","article-title":"Effects of canagliflozin on serum magnesium in patients with type 2 diabetes mellitus: a post hoc analysis of randomized controlled trials","volume":"8","author":"Gilbert","year":"2017","journal-title":"Diabetes Ther"},{"issue":"6","key":"10.1016\/j.jtumed.2026.07.003_bib5","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1111\/dom.13251","article-title":"Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled type 2 diabetes despite diet and exercise","volume":"20","author":"Aronson","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.jtumed.2026.07.003_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-021-89752-w","article-title":"SGLT-2 inhibitors associated euglycemic and hyperglycemic diabetic ketoacidosis: a multicentric cohort study","volume":"11","author":"Ata","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtumed.2026.07.003_bib8","first-page":"1","article-title":"Peripheral artery disease in type 2 diabetes mellitus","volume":"11","author":"Barbera-Guarderas","year":"2020","journal-title":"J Prim Care Community Health"},{"issue":"9896","key":"10.1016\/j.jtumed.2026.07.003_bib12","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S0140-6736(13)60683-2","article-title":"Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes","volume":"382","author":"Cefalu","year":"2013","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jtumed.2026.07.003_bib13","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/dom.13879","article-title":"Favourable effect of the sodium\u2013glucose cotransporter-2 inhibitor canagliflozin plus the dipeptidyl peptidase-4 inhibitor teneligliptin in combination on glycaemic fluctuation: the CALMER study","volume":"22","author":"Cho","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"10.1016\/j.jtumed.2026.07.003_bib22","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1007\/s00125-016-4101-6","article-title":"Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials","volume":"59","author":"Tang","year":"2016","journal-title":"Diabetologia"},{"issue":"8","key":"10.1016\/j.jtumed.2026.07.003_bib21","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.2337\/dc17-1525","article-title":"Analysis of fractures in patients with type 2 diabetes treated with empagliflozin in pooled phase II and III trials and a head-to-head study","volume":"41","author":"Kohler","year":"2018","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.jtumed.2026.07.003_bib15","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.12937","article-title":"Sodium\u2013glucose cotransporter 2 inhibitors for type 2 diabetes mellitus","volume":"71","author":"Dandona","year":"2017","journal-title":"Int J Clin Pract"}],"container-title":["Journal of Taibah University Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658361226000892?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658361226000892?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T15:16:04Z","timestamp":1787411764000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1658361226000892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1658361226000892"],"URL":"https:\/\/doi.org\/10.1016\/j.jtumed.2026.07.003","relation":{},"ISSN":["1658-3612"],"issn-type":[{"value":"1658-3612","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of dapagliflozin on mineral homeostasis in patients with type 2 diabetes: A real-world retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Journal of Taibah University Medical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtumed.2026.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}